References
1. Schunemann HJ, Al-Ansary LA, Forland F, et al. Guidelines
International Network: Principles for Disclosure of Interests and
Management of Conflicts in Guidelines. Ann Intern Med . Oct 6
2015;163(7):548-53. doi:10.7326/M14-1885
2. Institute of Medicine. Clinical Practice Guidelines We Can
Trust . The National Academies Press; 2011:290.
3. Murayama A, Kamamoto S, Murata N, et al. Evaluation of financial
conflicts of interest and quality of evidence in Japanese
gastroenterology clinical practice guidelines. J Gastroenterol
Hepatol . Apr 2023;38(4):565-573. doi:10.1111/jgh.16089
4. Mamada H, Murayama A, Kamamoto S, et al. Evaluation of Financial and
Nonfinancial Conflicts of Interest and Quality of Evidence Underlying
Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal
Payments From Pharmaceutical Companies and Authors’ Self-Citation Rate
in Japan and the United States. Arthritis Care Res (Hoboken) . Jun
2023;75(6):1278-1286. doi:10.1002/acr.25032
5. Murayama A, Yamada K, Yoshida M, et al. Evaluation of Conflicts of
Interest among Participants of the Japanese Nephrology Clinical Practice
Guideline. Clin J Am Soc Nephrol . Jun 2022;17(6):819-826.
doi:10.2215/CJN.14661121
6. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T.
Pharmaceutical company payments to authors of the Japanese Clinical
Practice Guidelines for Hepatitis C treatment. Liver Int . Mar
2021;41(3):464-469. doi:10.1111/liv.14761
7. Harada K, Ozaki A, Saito H, et al. Financial payments made by
pharmaceutical companies to the authors of Japanese hematology clinical
practice guidelines between 2016 and 2017. Health Policy . Mar
2021;125(3):320-326. doi:10.1016/j.healthpol.2020.12.005
8. Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, Bero L.
Undisclosed financial ties between guideline writers and pharmaceutical
companies: a cross-sectional study across 10 disease categories.BMJ Open . Feb 5 2019;9(2):e025864.
doi:10.1136/bmjopen-2018-025864
9. Tabatabavakili S, Khan R, Scaffidi MA, Gimpaya N, Lightfoot D, Grover
SC. Financial Conflicts of Interest in Clinical Practice Guidelines: A
Systematic Review. Mayo Clin Proc Innov Qual Outcomes . Apr
2021;5(2):466-475. doi:10.1016/j.mayocpiqo.2020.09.016
10. Steinbrook R. Guidance for guidelines. N Engl J Med . Jan 25
2007;356(4):331-3. doi:10.1056/NEJMp068282
11. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP, Guideline Panel
Review Working G. Ensuring the integrity of clinical practice
guidelines: a tool for protecting patients. BMJ . Sep 17
2013;347:f5535. doi:10.1136/bmj.f5535
12. Nejstgaard CH, Bero L, Hrobjartsson A, Jorgensen AW, Jorgensen KJ,
Le M, Lundh A. Association between conflicts of interest and favourable
recommendations in clinical guidelines, advisory committee reports,
opinion pieces, and narrative reviews: systematic review. BMJ .
Dec 9 2020;371:m4234. doi:10.1136/bmj.m4234
13. Brems JH, Davis AE, Clayton EW. Analysis of conflict of interest
policies among organizations producing clinical practice guidelines.PLOS ONE . 2021;16(4):e0249267. doi:10.1371/journal.pone.0249267
14. Ngo-Metzger Q, Moyer V, Grossman D, et al. Conflicts of Interest in
Clinical Guidelines: Update of U.S. Preventive Services Task Force
Policies and Procedures. Am J Prev Med . Jan 2018;54(1S1):S70-S80.
doi:10.1016/j.amepre.2017.06.034
15. Norris SL, Holmer HK, Burda BU, Ogden LA, Fu R. Conflict of interest
policies for organizations producing a large number of clinical practice
guidelines. PLoS One . 2012;7(5):e37413.
doi:10.1371/journal.pone.0037413
16. Ahlawat A, Narayanaswami P. Financial relationships between
neurologists and industry: The 2015 Open Payments database.Neurology . May 21 2019;92(21):1006-1013.
doi:10.1212/wnl.0000000000007640
17. Messé SR, Smith EE, Getchius TSD, Gronseth GS. American Academy of
Neurology replies to Jeanne Lenzer. BMJ : British Medical
Journal . 2013;347:f5324. doi:10.1136/bmj.f5324
18. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T.
Financial and Intellectual Conflicts of Interest Among Japanese Clinical
Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol
Head Neck Surg . May 2022;166(5):869-876. doi:10.1177/01945998211034724
19. Murayama A, Hoshi M, Saito H, et al. Nature and Trends in Personal
Payments Made to the Respiratory Physicians by Pharmaceutical Companies
in Japan between 2016 and 2019. Respiration .
2022;101(12):1088-1098. doi:10.1159/000526576
20. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T,
Akihiko O. Undisclosed financial conflicts of interest with
pharmaceutical companies among the authors of the Esophageal Cancer
Practice Guidelines 2017 by the Japan Esophageal Society. Dis
Esophagus . Oct 14 2022;35(10)doi:10.1093/dote/doac056
21. Murayama A. Financial Conflicts of Interest Among the Authors of the
Clinical Practice Guidelines for Rheumatoid Arthritis in Japan.Cureus . Oct 2023;15(10):e46650. doi:10.7759/cureus.46650
22. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T.
Financial conflicts of interest between pharmaceutical companies and the
authors of urology clinical practice guidelines in Japan. Int
Urogynecol J . Feb 2021;32(2):443-451. doi:10.1007/s00192-020-04547-3
23. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A.
Evaluation of financial conflicts of interest and drug statements in the
coronavirus disease 2019 clinical practice guideline in Japan.Clin Microbiol Infect . Mar 2022;28(3):460-462.
doi:10.1016/j.cmi.2021.11.019
24. Murayama A, Ozaki A, Saito H, et al. Pharmaceutical company payments
to dermatology Clinical Practice Guideline authors in Japan. PLoS
One . 2020;15(10):e0239610. doi:10.1371/journal.pone.0239610
25. Murayama A, Shin N, Higuchi K, Kohli I, Kugo H, Senoo Y. Financial
conflicts of interest between infectious diseases clinical practice
guideline authors and the pharmaceutical industry in Japan. Infect
Dis (Lond) . Feb 1 2024:1-5. doi:10.1080/23744235.2024.2309351
26. Murayama A, Miyazawa K, Kamamoto S, Shigeta H, Kugo H, Higuchi K,
Senoo Y. Financial conflicts of interest in Japanese obstetrics and
gynaecology clinical practice guidelines. Clinical and
Translational Discovery . 2024/02/01 2024;4(1):e273.
doi:10.1002/ctd2.273
27. Senoo Y, Saito H, Ozaki A, et al. Pharmaceutical company payments to
authors of the Japanese guidelines for the management of hypertension.Medicine (Baltimore) . Mar 26 2021;100(12):e24816.
doi:10.1097/MD.0000000000024816
28. Murayama A. Financial Conflicts of Interest Among the Authors of the
Clinical Practice Guidelines for Rheumatoid Arthritis in Japan.Cureus . 2023;15(10)
Table 1. Summary of personal payments to Japanese neurology guideline
authors between 2016 and 2020